References

1. Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7: 573-584 [CrossRef] [Google Scholar] [PubMed]
2. Cossa G, Gatti L, Zunino F, Perego P (2009) Strategies to improve the efficacy of platinum compounds. Curr Med Chem 16: 2355-2365 [CrossRef] [Google Scholar] [PubMed]
3. Bartek J, Lukas J (2003) Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3: 421-429 [CrossRef] [Google Scholar] [PubMed]
4. Pommier Y, Weinstein JN, Aladjem MI, Kohn KW (2006) Chk2 molecular interaction map and rationale for Chk2 inhibitors. Clin Cancer Res 12: 2657-2661 [CrossRef] [Google Scholar] [PubMed]
5. Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205: 275-292 [CrossRef] [Google Scholar] [PubMed]
6. Redmond KM, Wilson TR, Johnston PG, Longley DB (2008) Resistance mechanisms to cancer chemotherapy. Front Biosci 13: 5138-5154 [CrossRef] [Google Scholar] [PubMed]
7. Fojo T (2002) p53 as a therapeutic target: unresolved issues on the road to cancer therapy targeting mutant p53. Drug Resist Updat 5: 209-216 [CrossRef] [Google Scholar] [PubMed]
8. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311 [Google Scholar] [PubMed]
9. Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, et al. (2001) Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 7: 2984-2997 [Google Scholar] [PubMed]
10. Hirao A, Cheung A, Duncan G, Girard PM, Elia AJ, et al. (2002) Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)- dependent and an ATM-independent manner. Mole Cell Biol 22: 6521- 6532 [CrossRef] [Google Scholar] [PubMed]
11. Yu Q, Rose JH, Zhang H, Pommier Y (2001) Antisense inhibition of Chk2/ hCds1 expression attenuates DNA damage-induced S and G2 checkpoints and enhances apoptotic activity in HEK-293 cells. FEBS Lett 505: 7-12 [CrossRef] [Google Scholar] [PubMed]
12. Liang X, Guo Y, Figg WD, Fojo AT, Mueller MD, et al. (2011) The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 Inhibitor. Chemother Res Pract 2011: 715469 [CrossRef] [Google Scholar] [PubMed]
13. Antoni L, Sodha N, Collins I, Garrett MD (2007) CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin? Nature Reviews Cancer 7: 925-936 [CrossRef] [Google Scholar] [PubMed]
14. Ghosh JC, Dohi T, Raskett CM, Kowalik TF, Altieri DC (2006) Activated checkpoint kinase 2 provides a survival signal for tumor cells. Cancer Res 66: 11576-11579 [CrossRef] [Google Scholar] [PubMed]
15. Huang JC, Svoboda DL, Reardon JT, Sancar A (1992) Human nucleotide excision nuclease removes thymine dimers from DNA by incising the 22nd phosphodiester bond 5' and the 6th phosphodiester bond 3' to the photodimer. Proc Natl Acad Sci U S A 89: 3664-3668 [CrossRef] [Google Scholar] [PubMed]
16. Moggs JG, Yarema KJ, Essigmann JM, Wood RD (1996) Analysis of incision sites produced by human cell extracts and purified proteins during nucleotide excision repair of a 1,3-intrastrand d(GpTpG)- cisplatin adduct. J Biol Chem 271: 7177-7186 [CrossRef] [Google Scholar] [PubMed]
17. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, et al. (2002) Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 62: 4899-4902 [Google Scholar] [PubMed]
18. Reed E (2006) ERCC1 measurements in clinical oncology. N Engl J Med 355: 1054-1055 [CrossRef] [Google Scholar] [PubMed]
19. Yu JJ, Dabholkar M, Bennett WP, Welsh JA, Mu CJ, et al. (1996) Platinumsensitive and platinum-resistant ovarian cancer tissues show differences in the relationships between mRNA levels of p53, ERCC1 and XPA. Int J Oncol 8: 313-317 [CrossRef] [Google Scholar] [PubMed]
20. Sood AK, Buller RE (1996) Genomic instability in ovarian cancer: a reassessment using an arbitrarily primed polymerase chain reaction. Oncogene 13: 2499-2504 [Google Scholar] [PubMed]
21. Sancar A, Tang MS (1993) Nucleotide excision repair. Photochem Photobiol 57: 905-921 [CrossRef] [PubMed]
22. Matsunaga T, Mu D, Park CH, Reardon JT, Sancar A (1995) Human DNA repair excision nuclease. Analysis of the roles of the subunits involved in dual incisions by using anti-XPG and anti-ERCC1 antibodies. J Biol Chem 270: 20862-20869 [CrossRef] [Google Scholar] [PubMed]
23. Reardon JT, Sancar A (2002) Molecular anatomy of the human excision nuclease assembled at sites of DNA damage. Mol Cell Biol 22: 5938-5945 [CrossRef] [Google Scholar] [PubMed]
24. Hoeijmakers JH1 (1993) Nucleotide excision repair I: from E. coli to yeast. Trends Genet 9: 173-177 [CrossRef] [Google Scholar] [PubMed]
25. Wood RD (1997) Nucleotide excision repair in mammalian cells. J Biol Chem 272: 23465-23468 [CrossRef] [Google Scholar] [PubMed]
26. Petit C, Sancar A (1999) Nucleotide excision repair: from E. coli to man. Biochimie 81: 15-25 [CrossRef] [Google Scholar] [PubMed]
27. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E (1994) Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94: 703-708 [CrossRef] [Google Scholar] [PubMed]
28. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, et al. (1987) Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47: 414-418 [Google Scholar] [PubMed]
29. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, et al. (1992) ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84: 1512-1517 [CrossRef] [Google Scholar] [PubMed]
30. Masuda H, Ozols RF, Lai GM, Fojo A, Rothenberg M, et al. (1988) Increased DNA repair as a mechanism of acquired resistance to cisdiamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res 48: 5713-5716 [Google Scholar] [PubMed]
31. Chang IY, Kim MH, Kim HB, Lee DY, Kim SH, et al. (2005) Small interfering RNA induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. Biochem Biophysl Resh Commun 327: 225-233 [CrossRef] [Google Scholar] [PubMed]
32. Parker RJ, Eastman A, Bostick-Bruton F, Reed E (1991) Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 87: 772–777 [CrossRef] [Google Scholar] [PubMed]
33. Johnson SW, Perez RP, Godwin AK, Yeung AT, Handel LM, et al. (1994) Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem Pharmacol 47: 689-697 [CrossRef] [Google Scholar] [PubMed]
34. Li Q, Gardner K, Zhang L, Tsang B, Bostick-Bruton F, et al. (1998) Cisplatin induction of ERCC1 mRNA expression in A2780/CP70 human ovarian cancer cells. J Biol Chem 273: 23419-23425 [CrossRef] [Google Scholar] [PubMed]
35. Yan QW, Reed E, Zhong XS, Thornton K, Guo Y, et al. (2006) MZF1 possesses a repressively regulatory function in ERCC1 expression. Biochem Pharmacol 71: 761-771 [CrossRef] [Google Scholar] [PubMed]
36. Yu JJ, Mu C, Lee KB, Okamoto A, Reed EL, et al. (1997) A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat Res 382: 13-20 [CrossRef] [Google Scholar] [PubMed]
37. Isla D, Sarries C, Rosell R, Alonso G, Domine M, et al. (2004) Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15: 1194-1203 [CrossRef] [Google Scholar] [PubMed]
38. Ryu JS, Hong YC, Han HS, Lee JE,Kim S, et al. (2004) Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44: 311-316 [CrossRef] [Google Scholar] [PubMed]
39. Smith S, Su D, Rigault de la Longrais IA, Schwartz P, Puopolo M, et al. (2007) ERCC1 Genotype and Phenotype in Epithelial Ovarian Cancer Identify Patients Likely to Benefit From Paclitaxel Treatment in Addition to Platinum-Based Therapy. J Clin Oncol 25:5172-5179 [CrossRef] [Google Scholar] [PubMed]
40. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, et al. (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266: 807- 810 [CrossRef] [Google Scholar] [PubMed]
41. Yu JJ, Yang XQ, Song QH, Mueller MD, Remick SC (2014) Dicycloplatin, a novel platinum analog in chemotherapy: Synthesis of Chinese preclinical and clinical profile and emerging mechanistic studies. Anticancer Res 34: 455-464 [Google Scholar] [PubMed]
42. Yu JJ (2009) Unlocking the Molecular Mechanisms of DNA Repair and Platinum Drug Resistance in Cancer Chemotherapy. Current Drug Therapy 4: 19-28 [CrossRef] [Google Scholar]